A Complication of Percutaneous Sclerotherapy for Congenital Pulmonary Airway Malformation: Intravascular Injection and Cardiac Necrosis. Fetal Pediatr Pathol 2017 Dec;36(6):437-444
Date
12/06/2017Pubmed ID
29206544DOI
10.1080/15513815.2017.1346017Scopus ID
2-s2.0-85036607410 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
INTRODUCTION: A congenital pulmonary airway malformation (CPAM) type III may become large enough to cause hydrops fetalis. In such circumstances, the fetus can be treated with open fetal resection, maternal betamethasone administration, or percutaneous sclerotherapy.
CASE REPORT: A 24 week gestation fetus with a CPAM type III was treated by percutaneous sclerotherapy using ethanolamine oleate (EO). The EO inadvertently entered the left atrium and ventricle with subsequent fetal bradycardia and demise. Autopsy revealed myocardial necrosis.
CONCLUSION: Percutaneous sclerotherapy has been previously described in the literature for the treatment of microcystic CPAMs with secondary hydrops. This is the first reported case of an adverse event after fetal sclerotherapy.
Author List
H Chon A, Takeda MR, Felix JC, Chmait RHAuthor
Juan Felix MD Vice Chair, Director, Professor in the Pathology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAutopsy
Betamethasone
Bradycardia
Cystic Adenomatoid Malformation of Lung, Congenital
Female
Fetal Death
Heart Rate, Fetal
Humans
Hydrops Fetalis
Infant, Newborn
Lung
Myocardium
Necrosis
Oleic Acids
Pregnancy
Prognosis
Sclerotherapy
